Exocrine Pancreatic Insufficiency Growth Forecast 2025-2034: Trends, Opportunities, and Key Insights You Need to Know
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Predicted CAGR for the Exocrine Pancreatic Insufficiency Market Over the Forecast Period of 2025 to 2034?
In recent years, the exocrine pancreatic insufficiency market has experienced a significant rise in its size. The market is projected to expand from $2.59 billion in 2024 to $2.76 billion in 2025, indicating a compound annual growth rate (CAGR) of 6.6%. Factors that have driven growth during the historic period include heightened awareness and diagnosis rates, increased presence of digestive disorders, growth in the aged population and decline in pancreatic function, alongside an upsurge in gastrointestinal surgeries.
In the coming years, the market size for exocrine pancreatic insufficiency is projected to experience a significant growth. The market is projected to surge to $3.58 billion in 2029 with a 6.7% compound annual growth rate (CAGR). This growth during the prediction period can be linked to the continual increase in awareness and screening, the growing elderly population, the increase in chronic disease cases, improvements in access to healthcare for patients, and advancements in research and development for digestive health. The anticipated trends for this period include telehealth and digital health solutions, joint research efforts, a focus on pediatric epi, advances in regulations and expedited designations, market spread in developing economies, and upgrades in healthcare infrastructure.
What External and Internal Drivers Are Contributing to the Growth of the exocrine pancreatic insufficiency Market’s Growth?
The exocrine pancreatic insufficiency market is projected to see a significant growth as a result of the increase in chronic illnesses. These are medical conditions that persist for a long time, usually three months or longer. These underlying, elongated diseases can boost the chances of secondary complications such as exocrine pancreatic insufficiency. This calls for improved handling of these chronic conditions through medical therapies and interventions, offering individuals an extended lifespan. The World Health Organization for instance, stated in September 2023 that annually, 41 million lives are claimed by health conditions, with 74% of these mortalities resulting from non-communicable or chronic diseases globally. Hence, the surge in chronic diseases is anticipated to stimulate the growth of the exocrine pancreatic insufficiency market.
Exocrine Pancreatic Insufficiency Market Driver: Rising Diabetes Cases Promote the Growth of the Exocrine Pancreatic Insufficiency Market
Get Your Free Sample of the Global Exocrine Pancreatic Insufficiency Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13107&type=smp
Who Are the Top Companies Driving Innovation and Growth in the Exocrine Pancreatic Insufficiency Market?
Major companies operating in the exocrine pancreatic insufficiency market report are:
• Pfizer Inc._x000D_
• F. Hoffmann-La Roche AG_x000D_
• Merck & Co. Inc._x000D_
• Janssen Pharmaceuticals Inc._x000D_
• AbbVie Inc._x000D_
What Key Trends Are Currently Impacting the Exocrine Pancreatic Insufficiency Market’s Development?
Prominent organizations within the exocrine pancreatic insufficiency market are directing efforts towards the establishment of patient advocacy entities like comprehensive nutritional guidance programs. Such actions are aimed at boosting awareness, understanding, and handling of the disease among those affected. The key components of comprehensive nutritional guidance are custom-made dietary advice, formulated considering individual requirements, health issues, and lifestyle, and they focus on education, plans for meals, and practices promoting sustainable habits for improved overall health. For example, in June 2024, a nutrition enterprise based in Switzerland, Nestlé Health Science, introduced a GLP-1 nutrition support platform. The GLP-1 nutrition support platform by Nestlé Health Science provides personalized nutritional resources and professional advice for people on GLP-1 medication, with an emphasis on preserving muscle, gut health, and general wellness. Its main objective is to empower its users in their journey of managing weight by addressing distinct dietary necessities and nurturing community camaraderie.
Get Instant Access to the Global Exocrine Pancreatic Insufficiency Market Report with Swift Delivery!
What Are the Major Segments of the Exocrine Pancreatic Insufficiency Market and Their Role in Driving Growth?
The exocrine pancreatic insufficiency market covered in this report is segmented –
1) By Treatment: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Other Treatments
2) By Diagnosis: Imaging Tests, Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), Other Types
3) By Symptoms: Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss, Other Symptoms
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End Users: Hospitals, Specialty Clinics, Homecare
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Enteric-Coated Capsules, Non-Enteric-Coated Capsules, Powder Formulations
3) By Other Treatments: Medications, Surgical Interventions, Supportive Therapies
Which Geographical Regions Are Pioneering Growth in the Exocrine Pancreatic Insufficiency Market?
North America was the largest region in the exocrine pancreatic insufficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exocrine pancreatic insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Key Characteristics That Define the Exocrine Pancreatic Insufficiency Market?
Exocrine pancreatic insufficiency (EPI) is a medical condition characterized by the pancreas’s insufficient production or release of digestive enzymes into the small intestine. These enzymes are essential for the digestion and absorption of nutrients from food. Exocrine pancreatic insufficiency can lead to malnutrition and digestive symptoms, including diarrhea, abdominal pain, bloating, and weight loss.
Browse Through More Similar Reports By The Business Research Company:
Mineral And Bone Disorder Treatment Global Market Report 2024
Acute Spinal Cord Injury Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/acute-spinal-cord-injury-global-market-report
Acute Pancreatitis Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
